Canary Oncoceutics
Canary Oncoceutics leverages cutting-edge genomics technology to provide highly accurate and comprehensive genomic profiling tests, including Comprehensive Gene Profiling (CGP), focused panels, and circulating tumor DNA (ctDNA) tests. Their product suite includes Canary Acuity™, Canary Focus™, Canary Pulse™, Canary Stat™, Canary HRD™, and Canary Stat Heredit™. The company aims to empower patients and healthcare professionals with advanced tools for personalized cancer treatment and informed decision-making, offering insights into genetic mutations for diagnosis, prognosis, and targeted therapy selection. They emphasize their CLIA-certification and CAP-accreditation for solid and liquid tumors, and highlight their AI-powered insights and a commitment to stringent quality control. Canary Oncoceutics also engages in research, clinical studies, and partnerships to advance cancer diagnostics and treatment strategies.
Canary Oncoceutics
Canary Oncoceutics leverages cutting-edge genomics technology to provide highly accurate and comprehensive genomic profiling tests, including Comprehensive Gene Profiling (CGP), focused panels, and circulating tumor DNA (ctDNA) tests. Their product suite includes Canary Acuity™, Canary Focus™, Canary Pulse™, Canary Stat™, Canary HRD™, and Canary Stat Heredit™. The company aims to empower patients and healthcare professionals with advanced tools for personalized cancer treatment and informed decision-making, offering insights into genetic mutations for diagnosis, prognosis, and targeted therapy selection. They emphasize their CLIA-certification and CAP-accreditation for solid and liquid tumors, and highlight their AI-powered insights and a commitment to stringent quality control. Canary Oncoceutics also engages in research, clinical studies, and partnerships to advance cancer diagnostics and treatment strategies.